Nasdaq · CIK 0001821586
MLTX MoonLake Immunotherapeutics
Insider trading from SEC Form 4. Last filing Jul 29, 2026. Close $10.82 on Oct 9, 2026, +19% from the 52-week low and -51% from the high.
In brief
MoonLake Immunotherapeutics (MLTX) has 39 SEC Form 4 filings on file from 9 insiders, the latest filed on Jul 29, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 4 open-market sells worth $2.3M, net -$2.3M.
20 open-market trades have been scored at MLTX. The newest: Kristian Reich (Chief Scientific Officer) sold $22k of stock on Jul 27, 2026, filed Jul 29, 2026, scored 0 (weak), under a 10b5-1 plan. The largest of the 20 shown: Bvf Partners L P/il (director and 10% owner) sold $63M on Mar 31, 2026, scored 65 (notable). 2 insiders sold within 14 days of each other around Jul 21, 2026.
11 Form 144 notices of planned sales are on file, the latest filed Jul 15, 2026.
Last 90 days
Net insider value
-$2.3M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
4
$2.3M by 1 insider
Insiders on file
9
with a Form 4 at this company
Price and insider trades, last year
MLTXOct 9, 2026 · close 10.82
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at MoonLake Immunotherapeutics, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Kristian Reich Chief Scientific Officer sell | $22k 1,100 shares | -0% | +218% from low-68% from high | |
| 28Weak | Kristian Reich Chief Scientific Officer sell | $1.0M 52,448 shares | -2% | +221% from low-68% from high | |
| 26Weak | Kristian Reich Chief Scientific Officer sell | $878k 43,700 shares | -2% | +205% from low-69% from high | |
| 17Weak | Kristian Reich Chief Scientific Officer sell | $322k 16,105 shares | -1% | +220% from low-68% from high | |
| 38Weak | da Silva Jorge Santos Chief Executive Officer sell | $2.0M 102,225 shares | -4% | +219% from low-68% from high | |
| 44Moderate | da Silva Jorge Santos Chief Executive Officer sell | $957k 47,775 shares | -2% | +206% from low-69% from high | |
| 40Moderate | Matthias Bodenstedt Chief Financial Officer sell | $862k 39,120 shares | -3% | +255% from low-64% from high | |
| 32Weak | Matthias Bodenstedt Chief Financial Officer sell | $352k 17,876 shares | -2% | +207% from low-69% from high | |
| 28Weak | Kristian Reich Chief Scientific Officer sell | $2.9M 150,000 shares | -5% | +207% from low-69% from high | |
| 15Weak | Matthias Bodenstedt Chief Financial Officer sell | $273k 13,653 shares | -1% | +202% from low-70% from high | |
| 23Weak | Matthias Bodenstedt Chief Financial Officer sell | $47k 2,426 shares | -0% | +201% from low-70% from high | |
| 65Notable | da Silva Jorge Santos Chief Executive Officer sell | $2.8M 150,000 shares | -5% | +188% from low-71% from high | |
| 42Moderate | Matthias Bodenstedt Chief Financial Officer sell | $1.7M 87,795 shares | -7% | +211% from low-69% from high | |
| 65Notable | Bvf Partners L P/il director, owner sell | $63M 3,750,000 shares | -37% | +198% from low-70% from high | |
| 68Notable | Kristian Reich Chief Scientific Officer sell | $3.0M 202,908 shares | -100% | - | |
| 58Moderate | da Silva Jorge Santos Chief Executive Officer sell | $3.0M 200,000 shares | -6% | - | |
| 32Weak | Matthias Bodenstedt Chief Financial Officer buy | $99k 10,870 shares | +2% | - | |
| 53Moderate | Bihua Chen other sell | $47M 6,499,978 shares | -77% | - | |
| 45Moderate | Catherine Moukheibir director sell | $1.1M 23,500 shares | -100% | - | |
| 32Weak | Matthias Bodenstedt Chief Financial Officer sell | $5.9M 100,000 shares | -16% | +539% from low-4% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 15, 2026 | Reich Kristian Officer | 150,000 0.20% of outstanding | $2.9M | Jul 15, 2026 | $2.9M |
| Jun 30, 2026 | Santos da Silva Jorge Officer, CEO | 150,000 0.20% of outstanding | $3.0M | Jun 30, 2026 | $2.8M |
| Jun 15, 2026 | Reich Kristian Officer | 150,000 0.20% of outstanding | $2.9M | Jun 15, 2026 | none |
| Apr 10, 2026 | Jorge Pedro Santos Radeck D Silva CEO | 150,000 0.21% of outstanding | $2.8M | Apr 10, 2026 | none |
| Apr 9, 2026 | Bodenstedt Matthias Officer, CFO | 160,870 0.22% of outstanding | $3.0M | Apr 9, 2026 | none |
| Mar 31, 2026 | BVF PARTNERS L P/IL 10% Stockholder, Affiliate of Director | 3,750,000 5.23% of outstanding | $63M | Mar 31, 2026 | none |
| Dec 8, 2025 | Kristian Dieter Johannes Reich Officer, Director, Chief Scientific Officer | 202,908 0.32% of outstanding | $3.0M | Dec 8, 2025 | none |
| Dec 8, 2025 | Jorge Pedro Santos Radeck Da Silva Officer, Director, CEO | 200,000 0.31% of outstanding | $3.0M | Dec 8, 2025 | none |
| Jul 3, 2025 | Moukheibir Catherine Director | 23,500 0.04% of outstanding | $1.1M | Jul 3, 2025 | none |
| Dec 20, 2023 | Bodenstedt Matthias Officer, CFO | 5,264 0.01% of outstanding | $312k | Dec 20, 2023 | $5.6M |
| Dec 19, 2023 | Bodenstedt Matthias Officer, CFO | 94,736 0.16% of outstanding | $5.6M | Dec 19, 2023 | none |
Transactions
The newest 50 of 65 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | Kristian Reich Chief Scientific Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -1,100 | $20.00 | $22k | 2,711,198 | Jul 29, 2026 |
| Jul 21, 2026 | Kristian Reich Chief Scientific Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -50,000 | $20.02 | $1.0M | 2,714,746 | Jul 23, 2026 |
| Jul 22, 2026 | Kristian Reich Chief Scientific Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -2,448 | $20.00 | $49k | 2,712,298 | Jul 23, 2026 |
| Jul 20, 2026 | Kristian Reich Chief Scientific Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -43,700 | $20.09 | $878k | 2,764,746 | Jul 21, 2026 |
| Jul 15, 2026 | Kristian Reich Chief Scientific Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -16,105 | $20.01 | $322k | 2,808,446 | Jul 20, 2026 |
| Jul 9, 2026 | da Silva Jorge Santos Chief Executive Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -33,936 | $20.01 | $679k | 2,843,182 | Jul 13, 2026 |
| Jul 10, 2026 | da Silva Jorge Santos Chief Executive Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -68,289 | $20.02 | $1.4M | 2,774,893 | Jul 13, 2026 |
| Jul 1, 2026 | da Silva Jorge Santos Chief Executive Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -47,775 | $20.03 | $957k | 2,877,118 | Jul 2, 2026 |
| Jun 22, 2026 | Matthias Bodenstedt Chief Financial Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -39,120 | $22.04 | $862k | 1,115,435 | Jun 23, 2026 |
| Jun 17, 2026 | Bvf Partners L P/il director, owner | AGrant or award Option to Buyderivativeindirect: See footnote | +22,195 | $0.00 | $0 | 22,195 | Jun 22, 2026 |
| Jun 17, 2026 | Catherine Moukheibir director | AGrant or award Option to Buyderivative | +22,195 | $0.00 | $0 | 22,195 | Jun 18, 2026 |
| Jun 17, 2026 | Andrew John Phillips director | AGrant or award Option to Buyderivative | +22,195 | $0.00 | $0 | 22,195 | Jun 18, 2026 |
| Jun 17, 2026 | Matthias Bodenstedt Chief Financial Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -15,082 | $19.68 | $297k | 1,157,349 | Jun 18, 2026 |
| Jun 17, 2026 | Spike Loy director | AGrant or award Option to Buyderivative | +22,195 | $0.00 | $0 | 22,195 | Jun 18, 2026 |
| Jun 17, 2026 | Ramnik Xavier director | AGrant or award Option to Buyderivative | +22,195 | $0.00 | $0 | 22,195 | Jun 18, 2026 |
| Jun 18, 2026 | Matthias Bodenstedt Chief Financial Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -2,794 | $19.60 | $55k | 1,154,555 | Jun 18, 2026 |
| Jun 15, 2026 | Kristian Reich Chief Scientific Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -50,000 | $18.89 | $945k | 2,924,551 | Jun 17, 2026 |
| Jun 16, 2026 | Kristian Reich Chief Scientific Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -50,000 | $18.70 | $935k | 2,874,551 | Jun 17, 2026 |
| Jun 17, 2026 | Kristian Reich Chief Scientific Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per shareindirect: See footnote.10b5-1 | -50,000 | $19.43 | $972k | 2,824,551 | Jun 17, 2026 |
| May 11, 2026 | Matthias Bodenstedt Chief Financial Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -13,653 | $20.02 | $273k | 1,172,431 | May 13, 2026 |
| Apr 14, 2026 | Matthias Bodenstedt Chief Financial Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -2,426 | $19.56 | $47k | 1,186,084 | Apr 16, 2026 |
| Apr 10, 2026 | da Silva Jorge Santos Chief Executive Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per share | -98,127 | $18.41 | $1.8M | 2,976,766 | Apr 14, 2026 |
| Apr 13, 2026 | da Silva Jorge Santos Chief Executive Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per share | -51,873 | $18.23 | $946k | 2,924,893 | Apr 14, 2026 |
| Apr 9, 2026 | Matthias Bodenstedt Chief Financial Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -85,870 | $18.94 | $1.6M | 1,190,435 | Apr 10, 2026 |
| Apr 10, 2026 | Matthias Bodenstedt Chief Financial Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -1,925 | $19.51 | $38k | 1,188,510 | Apr 10, 2026 |
| Mar 31, 2026 | Bvf Partners L P/il director, owner | SOpen-market sale Class A Ordinary Shares, $0.0001 par value | -1,932,354 | $16.79 | $32M | 8,302,735 | Apr 2, 2026 |
| Mar 31, 2026 | Bvf Partners L P/il director, owner | SOpen-market sale Class A Ordinary Shares, $0.0001 par value | -1,569,116 | $16.79 | $26M | 6,599,722 | Apr 2, 2026 |
| Mar 31, 2026 | Bvf Partners L P/il director, owner | SOpen-market sale Class A Ordinary Shares, $0.0001 par value | -248,530 | $16.79 | $4.2M | 1,039,238 | Apr 2, 2026 |
| Jan 7, 2026 | Matthias Bodenstedt Chief Financial Officer | AGrant or award Class A ordinary shares, par value $0.0001 per share | +354,296 | $0.00 | $0 | 1,276,305 | Jan 9, 2026 |
| Jan 7, 2026 | Kristian Reich Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +520,342 | $0.00 | $0 | 520,342 | Jan 9, 2026 |
| Jan 7, 2026 | da Silva Jorge Santos Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +520,342 | $0.00 | $0 | 520,342 | Jan 9, 2026 |
| Dec 19, 2025 | Matthias Bodenstedt Chief Financial Officer | CConversion Class A ordinary shares, par value $0.0001 per share | +294,473 | - | - | 922,009 | Dec 22, 2025 |
| Dec 19, 2025 | da Silva Jorge Santos Chief Executive Officer | CConversion Class A ordinary shares, par value $0.0001 per share | +196,316 | - | - | 3,074,893 | Dec 22, 2025 |
| Dec 19, 2025 | Kristian Reich Chief Scientific Officer | CConversion Class A ordinary shares, par value $0.0001 per share | +35,389 | - | - | 35,389 | Dec 22, 2025 |
| Dec 19, 2025 | Matthias Bodenstedt Chief Financial Officer | DDisposition to issuer Class C ordinary shares, par value $0.0001 per share | -294,473 | - | - | 0 | Dec 22, 2025 |
| Dec 19, 2025 | da Silva Jorge Santos Chief Executive Officer | DDisposition to issuer Class C ordinary shares, par value $0.0001 per share | -196,316 | - | - | 0 | Dec 22, 2025 |
| Dec 19, 2025 | Kristian Reich Chief Scientific Officer | DDisposition to issuer Class C ordinary shares, par value $0.0001 per share | -35,389 | - | - | 0 | Dec 22, 2025 |
| Dec 19, 2025 | Matthias Bodenstedt Chief Financial Officer | CConversion Common shares, par value CHF 0.10 per share, of MoonLake AGderivative | -8,754 | - | - | 0 | Dec 22, 2025 |
| Dec 19, 2025 | da Silva Jorge Santos Chief Executive Officer | CConversion Common shares, par value CHF 0.10 per share, of MoonLake AGderivative | -5,836 | - | - | 0 | Dec 22, 2025 |
| Dec 19, 2025 | Kristian Reich Chief Scientific Officer | CConversion Common shares, par value CHF 0.10 per share, of MoonLake AGderivative | -1,052 | - | - | 0 | Dec 22, 2025 |
| Dec 8, 2025 | Kristian Reich Chief Scientific Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per share | -130,000 | $15.08 | $2.0M | 72,908 | Dec 10, 2025 |
| Dec 8, 2025 | da Silva Jorge Santos Chief Executive Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per share | -130,000 | $15.08 | $2.0M | 2,948,577 | Dec 10, 2025 |
| Dec 9, 2025 | Kristian Reich Chief Scientific Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per share | -72,908 | $14.43 | $1.1M | 0 | Dec 10, 2025 |
| Dec 9, 2025 | da Silva Jorge Santos Chief Executive Officer | SOpen-market sale Class A ordinary shares, par value $0.0001 per share | -70,000 | $14.49 | $1.0M | 2,878,577 | Dec 10, 2025 |
| Oct 8, 2025 | Matthias Bodenstedt Chief Financial Officer | POpen-market purchase Class A ordinary shares, par value $0.0001 per share | +10,870 | $9.09 | $99k | 627,536 | Oct 9, 2025 |
| Sep 29, 2025 | Bihua Chen other | SOpen-market sale Class A Ordinary Sharesindirect: See Footnotes | -70,748 | $9.38 | $664k | 8,423,403 | Oct 1, 2025 |
| Sep 29, 2025 | Bihua Chen other | SOpen-market sale Class A Ordinary Sharesindirect: See Footnotes | -232,460 | $8.40 | $2.0M | 8,190,943 | Oct 1, 2025 |
| Sep 29, 2025 | Bihua Chen other | SOpen-market sale Class A Ordinary Sharesindirect: See Footnotes | -3,390,943 | $7.58 | $26M | 4,800,000 | Oct 1, 2025 |
| Sep 29, 2025 | Bihua Chen other | SOpen-market sale Class A Ordinary Sharesindirect: See Footnotes | -2,800,000 | $6.61 | $19M | 2,000,000 | Oct 1, 2025 |
| Sep 30, 2025 | Bihua Chen other | SOpen-market sale Class A Ordinary Sharesindirect: See Footnotes | -5,827 | $6.96 | $41k | 1,994,173 | Oct 1, 2025 |
50 of 65 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Bvf Partners L P/ilother, owner, director
- Matthias BodenstedtChief Financial Officer
- Bihua Chenowner, other, ceo, chair, officer, director
- Spike Loydirector
- Catherine Moukheibirdirector
- Andrew John Phillipsdirector
- Kristian ReichChief Scientific Officer
- da Silva Jorge SantosChief Executive Officer
- Ramnik Xavierdirector
Questions about MLTX
Answered from the filings on this page, as of the latest one.
Are insiders buying MLTX?
As of Jul 29, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 4 open-market sells worth $2.3M by 1 insider at MoonLake Immunotherapeutics in the last 90 days, net -$2.3M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade MLTX on the open market?
Kristian Reich (Chief Scientific Officer) sold $22k of MLTX on Jul 27, 2026 and filed the Form 4 on Jul 29, 2026. InsiderTell scored 0 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at MoonLake Immunotherapeutics?
9 people have filed a Form 4 at MoonLake Immunotherapeutics, among them Bvf Partners L P/il (10% owner and director), Matthias Bodenstedt (Chief Financial Officer), Bihua Chen (10% owner, CEO, chair and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.